STOCK TITAN

Thomson Reuters: Thomson Investments owns 70.34%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Thomson Reuters Corporation (TRI) filed an ownership amendment reporting that Thomson Investments Limited beneficially owns 304,903,283 Common Shares, or 70.34% of the class. That amount includes 295,680,150 shares beneficially owned by The Woodbridge Company Limited and 9,223,133 beneficially owned by the family of the late Roy H. Thomson. The reported percentage is based on 433,458,865 shares outstanding as of November 2, 2026.

The company announced a Toronto Stock Exchange-approved normal course issuer bid to repurchase up to $500 million and up to 7 million Common Shares, approximately 1.6% of shares outstanding, from November 13, 2026 through November 12, 2027. Purchases from Woodbridge may begin November 13 on a basis proportionate to its interest; the automatic disposition plan provides for purchases during the TSX Special Trading Session on days the company also buys from other shareholders.

Participating entities sold 300,000 shares in open-market transactions on November 12 and 13. Average prices were $109.30 and $109.49 on US exchanges and CAD$155.85 and CAD$156.07 on Canadian exchanges, respectively.

Filing Explained

The reporting persons say they intend to maintain control; director deferred share units carry no votes and settle only after board service ends.

The reporting persons say they plan to maintain their controlling interest in Thomson Reuters. They report no current proposals for the listed corporate actions, though they may consider such plans in the future.

As of September 15, 2026, David K. R. Thomson, Peter J. Thomson, Michael Friisdahl and Michael Medline held 141,195, 18,943, 2,984 and 3,644 deferred share units, respectively. The units carry no voting rights and are fully vested when granted, but can be settled only after the director’s board service ends, in shares or, at Thomson Reuters’ election, cash; any shares delivered are purchased in the open market.

Beneficially owned Common Shares 304,903,283 shares Thomson Investments Limited; reported in the ownership amendment
Class ownership 70.34% Based on 433,458,865 Common Shares outstanding as of November 2, 2026
Common Shares outstanding 433,458,865 shares As of November 2, 2026
Normal course issuer bid amount Up to $500 million Repurchase program announced by Thomson Reuters
Maximum shares under bid Up to 7 million Common Shares Approximately 1.6% of shares outstanding; bid runs November 13, 2026 through November 12, 2027
Participating-entity sales 300,000 Common Shares Open-market sales on November 12 and 13, 2026
US exchange average sale prices $109.30 and $109.49 per share November 12 and November 13, 2026, respectively
Canadian exchange average sale prices CAD$155.85 and CAD$156.07 per share November 12 and November 13, 2026, respectively
normal course issuer bid regulatory
"under a new normal course issuer bid (NCIB)"
A Normal Course Issuer Bid is when a company buys back its own shares from the stock market over time. This usually shows that the company believes its stock is undervalued and wants to support its price, which can be important for investors to watch.
automatic disposition plan financial
"entered into an automatic disposition plan agreement"
Special Trading Session technical
"during the TSX's Special Trading Session"
deferred share units financial
"acquired 1,417 deferred share units as compensation"
Deferred share units are promises that give an executive or director the right to receive company shares or their cash value at a future date, often when they retire or leave the company. Think of them as a paycheck held in a savings account that converts into stock later; they matter to investors because they tie pay to long-term performance, create potential future dilution of shares, and represent a delayed cash or share obligation the company must eventually fulfill.
issuer bid exemption order regulatory
"receives, if applicable, an issuer bid exemption order"
An issuer bid exemption order is a special approval that allows a company to buy back its own shares without following some of the usual rules that protect investors. This order makes it easier for companies to repurchase their stock when they believe it’s a good investment, similar to a store offering a special sale to its own customers. For investors, it signals the company’s confidence in its value and can impact the stock’s market price.
beneficially owned regulatory
"304,903,283 Common Shares beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TRI shares does Thomson Investments Limited beneficially own?

Thomson Investments Limited beneficially owns 304,903,283 Common Shares, or 70.34% of the class. The amount includes 295,680,150 shares beneficially owned by The Woodbridge Company Limited and 9,223,133 beneficially owned by the family of the late Roy H. Thomson. The percentage is based on 433,458,865 shares outstanding as of November 2, 2026.

How large is TRI’s new normal course issuer bid, and when does it run?

The company’s Toronto Stock Exchange-approved normal course issuer bid permits repurchases of up to $500 million and up to 7 million Common Shares, approximately 1.6% of shares outstanding. The bid runs from November 13, 2026 through November 12, 2027.

How are Thomson Reuters shares purchased from Woodbridge under the new bid?

Purchases from The Woodbridge Company Limited may begin on November 13, 2026 and are on a basis proportionate to its percentage interest. They are made during the TSX Special Trading Session under an automatic disposition plan, on trading days when the company also purchases shares from other shareholders. If Woodbridge does not sell as required, except due to a market disruption event, the TSX exemption ceases to apply and further purchases from Woodbridge under the bid are not permitted.

At what average prices did participating entities sell TRI shares?

Participating entities sold 300,000 Common Shares in open-market transactions on November 12 and 13, 2026. On US exchanges, average prices were $109.30 on November 12 and $109.49 on November 13; on Canadian exchanges, they were CAD$155.85 and CAD$156.07, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





884903709

(CUSIP Number)
David Colman
65 Queen Street West, Suite 2400, Toronto
Ontario, Z4, M5H 2M8
(416)-364-8700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/11/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to rows 8 and 10 above, includes 295,680,150 common shares of Thomson Reuters Corporation ("Common Shares") beneficially owned by The Woodbridge Company Limited and subsidiaries and 9,223,133 Common Shares beneficially owned by the family of the late Roy H. Thomson, the first Lord Thomson of Fleet through various affiliated corporations. In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to row 13 above, based on 433,458,865 Common Shares outstanding as of November 2, 2026.


SCHEDULE 13D


THOMSON INVESTMENTS LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:11/13/2026
THE WOODBRIDGE COMPANY LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:11/13/2026
1908720 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:11/13/2026
1396164 Ontario Limited
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:11/13/2026
Woodbridge Investments Corporation
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:11/13/2026
1001810107 Ontario Limited
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:11/13/2026
KRT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
DKRT FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
DKRT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
DKRT FUNDING CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1000920847 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
MB FINANCE CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
TT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
TLT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
TLT ISSUE HOLDCO A CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
TLT ISSUE HOLDCO CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1761173 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
2677295 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1000919995 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1754693 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
PJT INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1000920848 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
PGF INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
PGF FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
LCC INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1000078931 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1000421133 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
LLD INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
2806335 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
JRD INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
2754783 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
GED INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
SEG FAMILY CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
TCM INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
DYM INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
BG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
ACG INVESTMENTS CORP.
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
1001404651 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026
2808194 ONTARIO LIMITED
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:11/13/2026

Keep reading